Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Typ-2 Diabetic Patients With Cardiovascular Disease and Subclinical Inflammation

Trial Profile

Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Typ-2 Diabetic Patients With Cardiovascular Disease and Subclinical Inflammation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms MicroVasc-DIVA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2019.
    • 29 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top